AR046783A1 - Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima - Google Patents

Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima

Info

Publication number
AR046783A1
AR046783A1 ARP040104478A ARP040104478A AR046783A1 AR 046783 A1 AR046783 A1 AR 046783A1 AR P040104478 A ARP040104478 A AR P040104478A AR P040104478 A ARP040104478 A AR P040104478A AR 046783 A1 AR046783 A1 AR 046783A1
Authority
AR
Argentina
Prior art keywords
alkyl
lower alkyl
cycloalkyl
group
phenyl
Prior art date
Application number
ARP040104478A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR046783A1 publication Critical patent/AR046783A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto de sal cíclica de amonio cuaternario caracterizado porque tiene la fórmula (1), en la que: n es 0 ó 1; cuando X es nitrógeno u oxígeno, Y no es nada; cuando Y es nitrógeno u oxígeno, X no es nada; T es un grupo sulfonilo (SO2) o carbonilo (CO); cuando T = CO, X es oxígeno o nitrógeno; Z- se selecciona entre el grupo compuesto por halo, CF3COO-, mesilato, tosilato, o cualquier otro contraión farmacéuticamente aceptable; R1 se selecciona entre el grupo compuesto por alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo inferior, alquenilo C3-8, fenilo no sustituido o sustituido, o fenil no sustituido o sustituido-alquilo inferior(C1-3); donde, cuando está sustituido, un grupo está sustituido con uno o más radicales seleccionados entre el grupo compuesto por alcoxi C1-8, halo, hidroxi, amino, ciano, trifluorometilo, alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo inferior, fenilo y fenil- alquilo inferior(C1-3); R2 se selecciona entre el grupo compuesto por alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo inferior, fenilo no sustituido o sustituido, o fenil no sustituido o sustituido-alquilo inferior(C1-3); donde, cuando está sustituido, un grupo está sustituido con uno o más radicales seleccionados entre el grupo compuesto por alcoxi C1-8, halo, hidroxi, amino, ciano, trifluorometilo, alquilo C1-8 ramificado o no ramificado, cicloalquil C3-8 y cicloalquil(C3-8)-alquilo inferior y anillos heterocíclicos; R3 se selecciona entre el grupo compuesto por uno de los siguientes grupos no sustituidos o sustituidos: fenilo, fenil-alquilo inferior(C1-6) tiofenilo, tiofenil-alquilo inferior(C1-6), furanilo, furanil-alquilo inferior(C1-6), piridinilo, piridinil-alquilo inferior(C1-6), imidazolilo, imidazolilo-alquilo inferior(C1-6), naftilo, naftil-alquilo inferior(C1-6) quinolinilo, quinolinil-alquilo inferior(C1-6), indolilo, indolil-alquilo inferior(C1-6), benzotiofenilo, benzotiofenil-alquilo inferior(C1-6), benzofuranilo, benzofuranil-alquilo inferior(C1-6), benzoimidazolilo, benzoimidazolil-alquilo inferior(C1-6), alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo inferior(C1-6), o alquenilo C3-8; donde, cuando está sustituido, un grupo está sustituido con uno o más radicales seleccionados entre el grupo compuestos por alcoxi C1-6, fenoxi, fenil-alcoxi(C1-3), halo, hidroxi, amino, ciano, trifluorometilo, metilenodioxi, etilenodioxi, propilenodioxi, butilenodioxi, alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8, cicloalquil(C3-8)-alquilo inferior, fenilo, fenil-alquilo inferior(C1-3) tiofenilo, tiofenil- alquilo inferior(C1-3), furanilo, furanil-alquilo inferior(C1-3), piridinilo, piridinil-alquilo inferior(C1-3), naftilo, naftil-alquilo inferior(C1-3) quinolinilo, quinolinil-alquilo inferior(C1-3), indolilo, indolil-alquilo inferior(C1-3), benzotiofenilo, benzotiofenil-alquilo inferior(C1-3), benzofuranilo, benzofuranil-alquilo inferior(C1-6), COOH, COR6, COOR6, CONHR6, CON(R6)2, COG, NHR6, N(R6)2, G', OCOR6, OCONHR6, NHCOR6, N(R6)COR6, NHCOOR6 y NHCONHR6; y R4 se selecciona entre el grupo compuesto alquilo C1-8 ramificado o no ramificado, cicloalquilo C3-8 o cicloalquil(C3-8)-alquilo inferior; o una sal farmacéuticamente aceptable del mismo. Composición farmacéutica para el tratamiento de enfermedades mediadas por el receptor muscarínico de acetilcolina, que comprende un compuesto de la fórmula (1) y un vehículo farmacéuticamente aceptable del mismo. Uso de un compuesto de la fórmula (1) para preparar una composición farmacéutica para inhibir la unión de acetilcolina a sus receptores en un mamífero en necesidad del mismo, siendo efectiva preferentemente para tratar una enfermedad mediada por el receptor muscarínico de acetilcolina, donde la acetilcolina se une a dicho receptor. La enfermedad puede ser enfermedad pulmonar obstructiva crónica, bronquitis crónica, asma, obstrucción respiratoria crónica, fibrosis pulmonar, enfisema pulmonar y rinitis alérgica.
ARP040104478A 2003-12-03 2004-12-01 Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima AR046783A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52676603P 2003-12-03 2003-12-03

Publications (1)

Publication Number Publication Date
AR046783A1 true AR046783A1 (es) 2005-12-21

Family

ID=34676649

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104478A AR046783A1 (es) 2003-12-03 2004-12-01 Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima

Country Status (20)

Country Link
US (1) US20070179180A1 (es)
EP (1) EP1694327A4 (es)
JP (1) JP2007513182A (es)
KR (1) KR20060123414A (es)
CN (1) CN1913895A (es)
AR (1) AR046783A1 (es)
AU (1) AU2004296208A1 (es)
BR (1) BRPI0417343A (es)
CA (1) CA2549273A1 (es)
IL (1) IL176078A0 (es)
IS (1) IS8522A (es)
MA (1) MA28218A1 (es)
MX (1) MXPA06006256A (es)
NO (1) NO20063032L (es)
PE (1) PE20050861A1 (es)
RU (1) RU2006123418A (es)
TW (1) TW200530226A (es)
UY (1) UY28646A1 (es)
WO (1) WO2005055941A2 (es)
ZA (1) ZA200604485B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050250A1 (es) * 2003-07-17 2005-04-08 Glaxo Group Ltd Antagonistas de los receptores muscarinicos de la acetilcolina
TW200528448A (en) * 2003-10-17 2005-09-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR046225A1 (es) * 2003-11-04 2005-11-30 Glaxo Group Ltd Compuesto de 8-azoniabiciclo(3.2.1)octano, composicion farmaceutica para el tratamiento de enfermedades mediadas por receptores de acetilcolina muscarinicos que lo comprende y uso del compuesto para preparar dicha composicion
JP2007528420A (ja) * 2004-03-11 2007-10-11 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US20070185148A1 (en) * 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
WO2005095407A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US7932247B2 (en) * 2004-11-15 2011-04-26 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2007016639A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
JP2009504768A (ja) 2005-08-18 2009-02-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
WO2008103426A1 (en) * 2007-02-23 2008-08-28 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
CL2009000248A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo [3,4-b] piridin-5-il, inhibidores de la fosfodiesterasa de tipo iv (pde4) y antagonista de receptores muscarinicos de acetilcolina (machr); composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles en el tratamiento de enferemedades respiratorias y alergicas
UY31637A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
UY31636A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482837B1 (en) * 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
CA2378499A1 (en) * 1999-08-04 2001-02-15 Teijin Limited Cyclic amine ccr3 antagonists
DE10063008A1 (de) * 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
DE10201550A1 (de) * 2002-01-17 2003-07-31 Merck Patent Gmbh Phenoxy-Piperidine

Also Published As

Publication number Publication date
ZA200604485B (en) 2007-11-28
RU2006123418A (ru) 2008-01-10
PE20050861A1 (es) 2005-12-10
EP1694327A2 (en) 2006-08-30
MA28218A1 (fr) 2006-10-02
AU2004296208A1 (en) 2005-06-23
US20070179180A1 (en) 2007-08-02
WO2005055941A3 (en) 2006-02-16
EP1694327A4 (en) 2009-11-25
IL176078A0 (en) 2006-10-05
BRPI0417343A (pt) 2007-03-13
UY28646A1 (es) 2005-06-30
NO20063032L (no) 2006-08-30
MXPA06006256A (es) 2006-08-23
WO2005055941A2 (en) 2005-06-23
TW200530226A (en) 2005-09-16
CN1913895A (zh) 2007-02-14
CA2549273A1 (en) 2005-06-23
KR20060123414A (ko) 2006-12-01
IS8522A (is) 2006-06-26
JP2007513182A (ja) 2007-05-24

Similar Documents

Publication Publication Date Title
AR046783A1 (es) Compuesto de sal ciclica de amonio cuaternario composicion farmaceutica que lo comprende y su uso para preparar esta ultima
ES2345044T3 (es) 2-piperazin-piridinas utiles para tratar el dolor.
BRPI0507495A (pt) composto, composição farmacêutica, uso do composto método para o tratamento de distúrbios mediados por mglur5, e, método para inibir a ativação de receptores de mglur5
AR110051A2 (es) Pirazolo[3,4-d]pirimidinas útiles para tratar trastornos respiratorios
WO2009006404A3 (en) Heterocyclic compounds useful as raf kinase inhibitors
AR048266A1 (es) Compuesto de benzazepina, composicion farmaceutica que lo comprende y su uso para prepararla
AR029887A1 (es) Compuestos para el tratamiento de la isquemia, su uso en la fabricacion de medicamentos y composiciones que los contienen
RU2007129090A (ru) Органические соединения
AR048317A1 (es) Derivados de benzoazepina como antagonistas del receptor muscarinico de acetilcolina y composiciones farmaceuticas.
TN2010000026A1 (fr) Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
AR041672A1 (es) Compuesto biciclico de benzamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para prepararlo
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
AR073480A1 (es) Benzamidas, su preparacion y su uso como medicamentos
NO20090327L (no) Nye forbindelser 384
AR054417A1 (es) Derivados de imidazol. proceso de obtencion y composiciones farmaceuticas.
BRPI0510623A (pt) compostos de derivados de prolina e morfolina
PE20070217A1 (es) Derivados de isoquinolona sustituidos con piperidinilo
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
AR064212A1 (es) Uso de profarmacos de analogos de gaba para tratar enfermedades
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
AR054411A1 (es) Combinacion farmaceutica que comprende un compuesto olefinico de 8- azoniabiciclo [ 3.2.1] octano y uno o mas ingredientes terapeuticos distintos, composicion farmaceutica que la comprende y uso de dichos componentes para prepararla
EP1313477A1 (en) Compounds and methods
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.

Legal Events

Date Code Title Description
FB Suspension of granting procedure